# Safety and Efficacy of Evolocumab in Ischemic Stroke

Study · id `cardio:ct-nct05697185` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05697185](<https://clinicaltrials.gov/study/NCT05697185>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05697185

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT05697185. Randomized; single masking; primary purpose treatment. Start 2023-02-01 (anticipated); primary completion 2024-02-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT05697185, source copy `cardio:ctgov-nct05697185-2023-01-25`, retrieved 2026-10-26)
- Planned start: 2023-02-01 (anticipated) (ClinicalTrials.gov record NCT05697185, source copy `cardio:ctgov-nct05697185-2023-01-25`, retrieved 2026-10-26)
- Primary completion: 2024-02-01 (anticipated) (ClinicalTrials.gov record NCT05697185, source copy `cardio:ctgov-nct05697185-2023-01-25`, retrieved 2026-10-26)
- Completion: 2024-12-01 (anticipated) (ClinicalTrials.gov record NCT05697185, source copy `cardio:ctgov-nct05697185-2023-01-25`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05697185-2023-01-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of Evolocumab in Ischemic Stroke
- Acronym: SEEIS
- Condition: Ischemic Stroke, Acute
- Intervention (Drug): Evolocumab
- Lead sponsor: Second Affiliated Hospital of Guangxi Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Evolocumab (`cardio:evolocumab`)

## Provenance

Content hash: 129ef45c1543eb0f79aa4515e177234689f293d5360bb34796d4e01873c2ab3b
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
